FDA Classifies Newborn Muscular Dystrophy Screening Test as Device
Published Date: 6/26/2025
Rule
Summary
The FDA is officially classifying the muscular dystrophy newborn screening test as a Class II device with special controls to ensure it’s safe and effective. This change helps babies get quicker access to this important test by easing some regulatory hurdles. The new classification is effective June 26, 2025, but has been in effect since December 12, 2019, making life easier for test makers and families alike.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Newborn Muscular Dystrophy Test Classified Class II
The FDA classified the muscular dystrophy newborn screening test as Class II (special controls). The device is defined as an in vitro diagnostic to measure creatine kinase from dried blood spot specimens from newborns. The order is effective June 26, 2025, and the classification was applicable on December 12, 2019.
Easier Pathway for Device Makers (510(k) Predicate)
By classifying this device into Class II via the De Novo process, the FDA allows the device to serve as a predicate so future devices of that type can be cleared through the less burdensome 510(k) process instead of De Novo or premarket approval. FDA received the De Novo request on November 4, 2019, and issued the classification order on December 12, 2019.
Mandatory Clinical Validation Study Requirements
Manufacturers must perform design verification and validation that include a clinical validation study demonstrating that the analyte identifies newborns needing follow-up, shows predictive value using well-characterized specimens, uses testing by representative users, assesses sample collection effects, and provides confirmed positive specimens with diagnostic outcome information. Data must demonstrate upper reference intervals including sufficient samples to calculate the 97.5th and 99.5th percentiles.
Labeling Must Show Warnings and Test Performance
Labeling must include warnings that results are not intended to diagnose muscular dystrophies and that results should be used with other clinical findings and confirmatory methods. Labels must provide detailed device performance information, including the false positive and false negative screen rates observed in the clinical study, any study limitations, and performance in relevant subgroups (for example, age at collection, birth weight, sex, gestational age).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11794, Medical Devices; Immunology and Microbiology Devices; Classification of the Herpes Simplex Virus Nucleic Acid-Based Assay for Central Nervous System Infections
The FDA is officially putting the herpes simplex virus test for brain infections into a safer, easier-to-manage category called Class II. This change means the test will have special rules to keep it safe and effective, helping patients get quicker access to this important tool without unnecessary red tape. The new classification is effective June 26, 2025, and could save time and money for makers and users of the test.
Next: 2025-11802, Special Local Regulation; Marine Events; Annual Bayview Mackinac Race, Lake Huron, MI
On July 12, 2025, from 10 a.m. to 3 p.m., the Coast Guard will control boat traffic around the Bayview Mackinac Race on Lake Huron to keep everyone safe. Boats can’t enter the race area without permission, and those allowed must move slowly and carefully. This helps protect racers, other boaters, and commercial ships during the event.